131 filings
8-K
SLRX
Salarius Pharmaceuticals, Inc.
15 Aug 24
Other Events
4:04pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
14 Aug 24
Other Events
4:09pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
25 Jul 24
Other Events
5:03pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
22 Jul 24
Other Events
5:39pm
8-K
SLRX
Salarius Pharmaceuticals, Inc.
19 Jul 24
Other Events
5:13pm
8-K
4vbqk
11 Jul 24
Other Events
8:15am
8-K
ela0bwbvb
17 Jun 24
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine
8:05am
8-K
j9p nwhmijb
14 Jun 24
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
4:04pm
8-K
mgpwui lm1wv
6 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:02pm
8-K
3lj287ofb4ir
22 Feb 24
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
5:55pm
8-K
fj4kurg aitbif
6 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:09pm
8-K
5qc ip9a2sgoi1wkt2x3
10 Aug 23
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
4:14pm
8-K
6skflcivc4do 9l6h87e
12 Jul 23
Other Events
9:22am
8-K
fpwe67ds8wt
14 Jun 23
Departure of Directors or Certain Officers
6:47pm
8-K
0c71tch7r0i3ku4p 6d
16 May 23
Salarius Pharmaceuticals Announces $6 Million Private Placement
4:33pm
8-K
nrz0vc908e4
13 Mar 23
Other Events
8:55am
8-K
7tn0fsaz
10 Jan 23
Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
11:11am
8-K
h0j5yu5j1i0p3g9fhi
1 Dec 22
Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
8:14am
8-K
y3jcrhv 76as9sxtusny
10 Nov 22
Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
8:38am
8-K
5klocnkj17oqef1
3 Nov 22
Other Events
9:28am